Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia

Ibrutinib is a targeted therapy drug that blocks the activity of Bruton's tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL). Side effects include infections, cytopenia, nausea, and diarrhoea. In this report, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tjønnfjord, Sara Kristina Viberg, Tjønnfjord, Eirik Brekka, Konopski, Zbigniew, Tjønnfjord, Geir Erland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553503/
https://www.ncbi.nlm.nih.gov/pubmed/34721911
http://dx.doi.org/10.1155/2021/1862446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553503/
https://www.ncbi.nlm.nih.gov/pubmed/34721911
http://dx.doi.org/10.1155/2021/1862446

Ejemplares similares